Aerie Pharmaceuticals Inc (NASDAQ:AERI) Q1 2018 Sentiment

July 27, 2018 - By Billy Entrekin

Sentiment for Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Aerie Pharmaceuticals Inc (NASDAQ:AERI) institutional sentiment decreased to 1.19 in Q1 2018. Its down -0.01, from 1.2 in 2017Q4. The ratio fall, as 76 institutional investors started new or increased equity positions, while 64 sold and reduced stock positions in Aerie Pharmaceuticals Inc. The institutional investors in our partner’s database reported: 39.43 million shares, up from 34.86 million shares in 2017Q4. Also, the number of institutional investors holding Aerie Pharmaceuticals Inc in their top 10 equity positions decreased from 7 to 4 for a decrease of 3. Sold All: 18 Reduced: 46 Increased: 59 New Position: 17.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $3.23 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

It closed at $71.4 lastly. It is down 8.48% since July 27, 2017 and is downtrending. It has underperformed by 21.05% the S&P500.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on August, 7. They expect $-1.01 earnings per share, down 23.17 % or $0.19 from last year’s $-0.82 per share. After $-1.05 actual earnings per share reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -3.81 % EPS growth.

Foresite Capital Management Ii Llc holds 30.19% of its portfolio in Aerie Pharmaceuticals, Inc. for 1.67 million shares. Dafna Capital Management Llc owns 132,770 shares or 3.5% of their US portfolio. Moreover, Sectoral Asset Management Inc has 3.2% invested in the company for 538,618 shares. The California-based Partner Fund Management L.P. has invested 3.12% in the stock. Healthcor Management L.P., a New York-based fund reported 1.20 million shares.

Since January 1, 0001, it had 2 buys, and 5 sales for $13.86 million activity.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Ratings analysis reveals 100% of Aerie Pharmaceuticals’s analysts are positive. Out of 3 Wall Street analysts rating Aerie Pharmaceuticals, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7700 while the high is $8700. The stock’s average target of $80.33 is 12.51% above today’s ($71.4) share price. AERI was included in 7 notes of analysts from February 16, 2018. The company was maintained on Thursday, March 1 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, May 9. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Tuesday, May 8. Cantor Fitzgerald has “Buy” rating and $8600 target. Mizuho maintained the shares of AERI in report on Wednesday, May 9 with “Buy” rating. The firm earned “Buy” rating on Thursday, March 29 by Mizuho. The firm earned “Buy” rating on Wednesday, February 28 by Cantor Fitzgerald. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright on Friday, February 16.

More important recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Fool.com which released: “Aerie Pharmaceuticals May Revolutionize Glaucoma Treatment” on July 24, 2018, also Bizjournals.com published article titled: “Durham pharma could be on its way to second FDA approval”, Businesswire.com published: “Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing” on July 16, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering” with publication date: July 13, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.